BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population

Stroke Clinical Trial

Official title:

A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population Combining Targeted and Unsupervised Biological Measurements With Non-Invasive Imaging Modalities to Identify Biomarkers That Predict Near Term (1-3-years) Outcomes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00738725
• Other study ID #: HRP-001
• Status: Completed
• Phase: N/A
• First received: August 19, 2008
• Last updated: January 26, 2015
• Start date: January 2008
• Est. completion date: December 2014

Study information

• Verified date: October 2013
• Source: BG Medicine, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The BioImage Study is a study of the characteristics of subclinical cardiovascular disease, as measured by imaging modalities, unsupervised circulating biomarker measurements, and risk factors that predict progression to overt clinical cardiovascular disease, in a diverse, population-based sample of 7,300 men (aged 55-80) and women (aged 60-80). The socio-demographics of the study population aims to mirror the US population as a whole with approximately 69% of the cohort will be white, 12% African-American, 13% Hispanic, 4% Asian, predominantly of Chinese descent and 2% other (U.S. Census Bureau: 2000).

The cohort will be recruited from the Humana Health Plan membership represented in three major US markets; Chicago, Illinois, Louisville, Kentucky and Southern Florida. Of the 7,300 participants, 6,000 will be characterized with respect to their Framingham risk score and various imaging features including coronary calcification, carotid intima-media thickness (IMT), presence of atherosclerotic plaques, and lower extremity vascular insufficiency as determined by the ankle brachial index (ABI). Blood samples will be assayed for putative biomarkers using a variety of methodologies including unsupervised proteomic and metabolomic profiling of plasma, RNA expression profiling and candidate gene analysis or genome wide scanning. These approaches will also be combined with targeted assays for particular analytes. Biological samples will be banked at the time of collection for these analyses and for additional follow on case-control and validation studies. Participants will be followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of Coronary Artery Disease (CAD), and stroke; mortality; and for cardiovascular disease interventions. The remaining 1,300 subjects will be evaluated and followed in a similar manner except no imaging studies will be conducted.

The study will be conducted using an innovative infrastructure and method of participant recruitment and enrollment. Mobile clinics containing the imaging equipment will travel to the three markets included in the study. The mobile clinic configuration allows for a high level of consistency in the data measurements which will be collected from diverse geographic areas and populations. Participants will be recruited based on claims monitoring to pre-determine eligibility. The baseline examinations of the 7,300 participants will occur over a 12-month period. Based on particular findings (Coronary Artery Calcium (CAC) score, Carotid Intima-Media Thickness (IMT), atherosclerotic plaque, Ankle Brachial Index (ABI), and presence of Abdominal Aortic Aneurysm (AAA), approximately 3,000 participants of the 6,000 imaging cohort will be referred for higher resolution imaging modalities to better characterize their arterial disease. This additional imaging will also be conducted at the mobile clinics and occur during the same 12-month period. Participants will be contacted every 6-months throughout the 3-year study to assess cardiovascular events, clinical morbidity and mortality, and to obtain additional blood samples.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7687
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

• Males Age: 55-80 years old;

• Females Age: 60-80 years old;

• Current Humana plan member;

• Resident in Chicago, Louisville, or South Florida

Exclusion Criteria:

• History of Coronary Heart Disease (CHD), including heart attack or angina;

• History of cerebrovascular disease (CVD), including stroke;

• History of peripheral arterial disease (PAD);

• History of or surgery for Abdominal Aortic Aneurysm (AAA);

• Having undergone procedures related to cardiovascular disease (CABG, angioplasty, valve replacement, pacemaker or defibrillator implantation, any surgery on the heart or arteries);

• Heart failure;

• Atrial fibrillation;

• Active treatment of cancer according to telephone survey response;

• Any serious medical condition which would prevent long-term participation or inability to complete the 3-year follow-up (e.g. Dementia, cognitive impairment or Alzheimer's Disease, advanced COPD);

• Weight > 350 lbs;

• Chest CT scan in the past year;

• Cognitive inability as judged by the telephone interviewer;

• Language barrier (speaks other than English);

• Inability to comply with visit to mobile clinic and other study requirements;

• Pregnancy (women > 60 years old are included only)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atherosclerotic Disease
• Heart Disease
• Heart Diseases
• Plaque
• Stroke

Locations

Country	Name	City	State
United States	Forest Med-Surg Center	Justice	Illinois
United States	North Ridge Medical Center	Oakland Park	Florida

Sponsors (6)

Lead Sponsor	Collaborator
BG Medicine, Inc	Abbott, AstraZeneca, Merck Sharp & Dohme Corp., Philips Medical Systems, Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify imaging and/or circulating biomarkers that predict 3-year cardiovascular events with incremental improvement over traditional risk assessment and to determine predictive value of biological and/or imaging markers for near-term (1-3year) outcomes		3-years or when 600 events have been observed	No